Genflow Biosciences plc (LON:GENF) (OTCQB:GENFF) is a UK-based biotech company with R&D facilities in Belgium and a U.S. office in Cambridge, MA, driven by one mission: to deliver therapeutics that potentially halt or slow the ageing process in humans and dogs. The company’s lead compound works through the delivery of a centenarian variant of the SIRT6 gene and has yielded promising preclinical results. Managed by an experienced team with decades of experience in the pharmaceutical and biotechnology sectors, the company is optimistic that development programs will continue at pace in the next 24 months.
